An Analysis of Adverse Events and Satisfaction Outcomes of Women Who Underwent Primary and Secondary Breast Augmentation Using Silimed® Breast Implants With Smooth Surface

Quality of Life Clinical Trial

— STEPS S  

Official title:

Post-market Monitoring and Control of Safety and Efficacy of Silimed® Breast Implants With Smooth Surface (STEPS S)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05345821
• Other study ID #: 6001022
• Status: Recruiting
• Start date: November 21, 2022
• Est. completion date: December 2034

Study information

• Verified date: January 2023
• Source: Silimed Industria de Implantes Ltda
• Contact: Ludmila C Donato
• Phone: +552198399-0573
• Email: Pesquisaclinica[@]silimed.com.br
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study investigates the safety and performance of Silimed® brand smooth surface breast implants in women born with indication for primary and secondary (revision) augmentation to be followed up for 10 years. The safety of the smooth-surfaced Silimed® implant will be evaluated by estimating known and unexpected short-term and long-term risk/adverse event rates through patient reports of adverse events after implantation. The performance of using Silimed® brand smooth surface breast implants will be evaluated by evaluating satisfaction and quality of life after implantation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 384
• Est. completion date: December 2034
• Est. primary completion date: December 2034
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Provide written informed consent
• Female at birth
• Be 18 years of age or older
• Have a complaint of hypomastia
• Have an indication for breast augmentation with silicone implants
• Ability to comply with the protocol throughout the follow-up period.

Exclusion Criteria:

• Replacement of breast implants due to a complication
• Breast reconstruction in at least one breast
• Informed pregnancy or breastfeeding at the time of inclusion
• Sequelae of mastopexy
• Ptosis requiring mastopexy
• Breast changes or lumps rated BI-RADS 3 or higher on preoperative ultrasound or mammograms
• Advanced fibrocystic disease at the time of implantation
• Neoplasia of any type not yet treated or undergoing treatment at the time of implantation, - Active infection not yet treated or undergoing treatment at any site at the time of implantation
• Report or record of adverse reactions or intolerance to silicone prior to implantation
• Report or record of immune diseases affecting the active or undergoing treatment (e.g. lupus erythematosus, discoid lupus, scleroderma, etc.) at the time of implantation
• Signs of inflammation of the breast or implant site at the time of implantation
• Increased risk of post-implantation complications -immediate surgical complications caused by illicit drug use or medication use
• Having participated in another clinical trial within 6 months prior to implant placement
• Any other condition which, based on the opinion of the investigator or designee, may prevent the provision of informed consent, make study participation unsafe, compromise protocol adherence, complicate the interpretation of study outcome data, or otherwise interfere with the achievement of study objectives

Related Conditions & MeSH terms

• Breast Implant; Complications
• Quality of Life
• Satisfaction

Locations

Country	Name	City	State
Brazil	Fundação do ABC - Centro universitário FMABC	Santo André	São Paulo

Sponsors (2)

Lead Sponsor	Collaborator
Silimed Industria de Implantes Ltda	Centro Universitário Saúde ABC

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Expected Adverse Events	Estimate the known short-term and long-term risk / adverse event rate for breast implant with smooth surface Silimed®	Every three years over the 10-year duration of the study
Primary	Unexpected Adverse Events	Estimate the unknown short-term and long-term risk / adverse event rate for breast implant with smooth surface Silimed®	Every three years over the 10-year duration of the study
Secondary	Patient's Satisfaction in Relation to Aesthetic Result	Estimate the performance of Silimed® breast implant with smooth surface through the satisfaction of the patient regarding the aesthetic result after breast augmentation. The assessment of patient's satisfaction will be done by means of a likert scale, where the following satisfaction options can be selected: 1 = definitely satisfied, 2 = satisfied, 3 = slightly satisfied, 4 = slightly dissatisfied and 5 = definitely unsatisfied.	Every three years over the 10-year duration of the study
Secondary	Patient's Satisfaction in General	Estimate the performance of Silimed® breast implants with smooth surface after breast augmentation by means of a questionnaire, the Breast Self-Assessment Questionnaire (BEQ-Brazil), which consist of 55 questions related to satisfaction and comfort with the overall appearance of the breasts.	Every three years over the 10-year duration of the study
Secondary	Evaluator's Satisfaction in Relation to Aesthetic Result	Estimate the performance of Silimed® breast implant with smooth surface througt the satisfaction of the evaluator regarding the aesthetic result after patient's breast augmentation. The assessment of evaluator's satisfaction will be done by means of a likert scale, where the following satisfaction options can be selected: 1 = definitely satisfied, 2 /= satisfied, 3= slightly satisfied, 4 = slightly dissatisfied and 5 = definitely unsatisfied.	Every three years over the 10-year duration of the study
Secondary	Patient's Quality of Life	Estimate the performance of Silimed® breast implant with smooth surface through the quality of life of the patient after breast augmentation. The assessment of patient's quality of life will be done by means of the Rosemberg Global Self-Esteem Scale, in order to evaluate the overall self-esteem of the sample.	Every three years over the 10-year duration of the study